Press release
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting
HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target
About this update from Compugen Ltd.
[{"type":"text","content":"\n HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at The 2019 AACR Annual Meeting in Atlanta, GA. In a poster titled \"Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors\", the Company reported that the fifth dose level patient cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were reported. Clinical and laboratory assessment for safety and tolerability are ongoing for this and earlier dose level patient cohorts. The poster presented at the meeting is available on Compugen's website.\nPatient enrolment and site engagement are on track in accordance with the Company's plans.\nUpdated information on the COM701 Phase 1 clinical study will be next featured in a trial-in-progress poster at The 2019 ASCO Annual Meeting taking place May 31-June 4, 2019 at McCormick Place, Chicago, IL.\nAbout the COM701 Phase 1 Study \nThis Phase 1 open-label clinical trial is designed to assess the safety and tolerability of administering escalating doses of COM701 monotherapy as well as combination administration with Bristol-Myers Squibb's Opdivo® in patients with advanced solid tumors. Additionally, the trial will evaluate evidence of preliminary antitumor activity of COM701 as monotherapy as well as in combination with Opdivo in patients with selected tumor types, including non-small cell lung cancer, ovarian cancer, breast cancer and endometrial cancer. \nThe Phase 1 Study, which is expected to enroll approximately 140 patients, is currently recruiting patients in five sites in the United States: The START center in San Antonio, Texas; The University of Tennessee West Cancer Center in Memphis, Tennessee; Sarah Cannon Research Institute in Nashville, Tennessee; Massachusetts General Hospital in Boston, Massachusetts; and the University of Chicago in Chicago, Illinois. Additional information is available here.\nAbout Compugen\nCompugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable computational discovery platforms to identify ...